Global Targeted Therapy Drugs for Leukemia Market Growth 2024-2030
The report requires updating with new data and is sent in 48 hours after order is placed.
Leukemia is a malignant clonal disease of hematopoietic stem cells. According to the degree of differentiation and maturity of leukemia cells and the natural history of the disease, leukemia is divided into two categories: acute leukemia (AL) and chronic leukemia (CL). Secondly, AL can be divided into acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) based on the mainly affected cell series. CL is divided into chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML, also known as chronic myelogenous leukemia) and rare types of leukemia. In the past decade or so, targeted drugs have made many breakthrough achievements in the clinical treatment of leukemia.
Targeted therapy drugs for leukemia are a class of medications designed to specifically target and inhibit the growth of cancer cells by interfering with specific molecules or pathways that play a key role in the development and progression of leukemia. These drugs work by blocking the activity of specific proteins or signaling pathways that are often overactive or mutated in leukemia cells, thereby slowing down or stopping the growth and spread of cancer cells while sparing normal cells. Examples of targeted therapy drugs for leukemia include tyrosine kinase inhibitors (TKIs), which target abnormal proteins involved in cell growth and survival, as well as monoclonal antibodies that bind to specific proteins on leukemia cells, triggering an immune response to attack and destroy the cancer cells. Targeted therapy drugs offer the potential for more precise and effective treatment options with fewer side effects compared to traditional chemotherapy, making them an important part of the treatment arsenal for various types of leukemia.
As a new trend in the treatment of leukemia, gene-targeted drugs will see more research and development in the future. Although this drug still has some problems, such as high price, drug resistance, etc., with the continuous advancement of science and technology and the continuous progress of medicine, it is believed that gene-targeted drugs will become an important means of treating leukemia.
The global Targeted Therapy Drugs for Leukemia market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.
LP Information, Inc. (LPI) ' newest research report, the “Targeted Therapy Drugs for Leukemia Industry Forecast” looks at past sales and reviews total world Targeted Therapy Drugs for Leukemia sales in 2023, providing a comprehensive analysis by region and market sector of projected Targeted Therapy Drugs for Leukemia sales for 2024 through 2030. With Targeted Therapy Drugs for Leukemia sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Targeted Therapy Drugs for Leukemia industry.
This Insight Report provides a comprehensive analysis of the global Targeted Therapy Drugs for Leukemia landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Targeted Therapy Drugs for Leukemia portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Targeted Therapy Drugs for Leukemia market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Targeted Therapy Drugs for Leukemia and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Targeted Therapy Drugs for Leukemia.
Leukemia occurs most often in adults older than 55 years, but it is the most common cancer in children younger than 15 years. Among adults, the most common types are CLL (35%) and AML (32%). Among children and teens, ALL is the most common, accounting for 75% of pediatric leukemia cases.
Globally, an estimated 440,000 new cases of leukemia are diagnosed each year along with 310,000 deaths. There will be an estimated 60,000 new cases of leukemia in the United States in 2023, and more than 24,000 related deaths. Survival rates vary substantially by leukemia subtype, ranging from a current five-year relative survival rate of 27% for adults diagnosed with AML to 86% for those with CLL, and 66% for children, adolescents, and young adults diagnosed with AML to 92% for those with ALL. In 2018, there are an estimated 381,774 people living with or in remission from leukemia in the United States. As the burden of leukemia grows, there will be a corresponding increase in the demand for effective treatment options, including targeted drugs.
The development of targeted drugs has transformed the treatment landscape for leukemia, offering improved efficacy and safety compared to traditional chemotherapy. Patients and healthcare providers increasingly prefer targeted therapies due to their ability to selectively attack cancer cells while sparing healthy tissues, leading to higher demand for these drugs.
This report presents a comprehensive overview, market shares, and growth opportunities of Targeted Therapy Drugs for Leukemia market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global Targeted Therapy Drugs for Leukemia market?
What factors are driving Targeted Therapy Drugs for Leukemia market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Targeted Therapy Drugs for Leukemia market opportunities vary by end market size?
How does Targeted Therapy Drugs for Leukemia break out by Type, by Application?
Leukemia is a malignant clonal disease of hematopoietic stem cells. According to the degree of differentiation and maturity of leukemia cells and the natural history of the disease, leukemia is divided into two categories: acute leukemia (AL) and chronic leukemia (CL). Secondly, AL can be divided into acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) based on the mainly affected cell series. CL is divided into chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML, also known as chronic myelogenous leukemia) and rare types of leukemia. In the past decade or so, targeted drugs have made many breakthrough achievements in the clinical treatment of leukemia.
Targeted therapy drugs for leukemia are a class of medications designed to specifically target and inhibit the growth of cancer cells by interfering with specific molecules or pathways that play a key role in the development and progression of leukemia. These drugs work by blocking the activity of specific proteins or signaling pathways that are often overactive or mutated in leukemia cells, thereby slowing down or stopping the growth and spread of cancer cells while sparing normal cells. Examples of targeted therapy drugs for leukemia include tyrosine kinase inhibitors (TKIs), which target abnormal proteins involved in cell growth and survival, as well as monoclonal antibodies that bind to specific proteins on leukemia cells, triggering an immune response to attack and destroy the cancer cells. Targeted therapy drugs offer the potential for more precise and effective treatment options with fewer side effects compared to traditional chemotherapy, making them an important part of the treatment arsenal for various types of leukemia.
As a new trend in the treatment of leukemia, gene-targeted drugs will see more research and development in the future. Although this drug still has some problems, such as high price, drug resistance, etc., with the continuous advancement of science and technology and the continuous progress of medicine, it is believed that gene-targeted drugs will become an important means of treating leukemia.
The global Targeted Therapy Drugs for Leukemia market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.
LP Information, Inc. (LPI) ' newest research report, the “Targeted Therapy Drugs for Leukemia Industry Forecast” looks at past sales and reviews total world Targeted Therapy Drugs for Leukemia sales in 2023, providing a comprehensive analysis by region and market sector of projected Targeted Therapy Drugs for Leukemia sales for 2024 through 2030. With Targeted Therapy Drugs for Leukemia sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Targeted Therapy Drugs for Leukemia industry.
This Insight Report provides a comprehensive analysis of the global Targeted Therapy Drugs for Leukemia landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Targeted Therapy Drugs for Leukemia portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Targeted Therapy Drugs for Leukemia market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Targeted Therapy Drugs for Leukemia and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Targeted Therapy Drugs for Leukemia.
Leukemia occurs most often in adults older than 55 years, but it is the most common cancer in children younger than 15 years. Among adults, the most common types are CLL (35%) and AML (32%). Among children and teens, ALL is the most common, accounting for 75% of pediatric leukemia cases.
Globally, an estimated 440,000 new cases of leukemia are diagnosed each year along with 310,000 deaths. There will be an estimated 60,000 new cases of leukemia in the United States in 2023, and more than 24,000 related deaths. Survival rates vary substantially by leukemia subtype, ranging from a current five-year relative survival rate of 27% for adults diagnosed with AML to 86% for those with CLL, and 66% for children, adolescents, and young adults diagnosed with AML to 92% for those with ALL. In 2018, there are an estimated 381,774 people living with or in remission from leukemia in the United States. As the burden of leukemia grows, there will be a corresponding increase in the demand for effective treatment options, including targeted drugs.
The development of targeted drugs has transformed the treatment landscape for leukemia, offering improved efficacy and safety compared to traditional chemotherapy. Patients and healthcare providers increasingly prefer targeted therapies due to their ability to selectively attack cancer cells while sparing healthy tissues, leading to higher demand for these drugs.
This report presents a comprehensive overview, market shares, and growth opportunities of Targeted Therapy Drugs for Leukemia market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Monoclonal Antibodies
- Small-Molecule Drugs
- Acute Myeloid Leukemia (AML)
- Chronic Myeloid Leukemia (CML)
- Acute Lymphoblastic Leukemia (ALL)
- Chronic Lymphocytic Leukemia (CLL)
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Novartis Pharms
- Bristol-Myers Squibb
- IL-Yang Pharms
- Pfizer
- Takeda Oncology
- Johnson & Johnson
- Gilead Sciences
- Abbvie
- Genentech
- Sanofi
- Amgen
- Roche
- GlaxoSmithKline
- AstraZeneca
- BeiGene
- Eli Lilly
- Merck
What is the 10-year outlook for the global Targeted Therapy Drugs for Leukemia market?
What factors are driving Targeted Therapy Drugs for Leukemia market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Targeted Therapy Drugs for Leukemia market opportunities vary by end market size?
How does Targeted Therapy Drugs for Leukemia break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Targeted Therapy Drugs for Leukemia Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Targeted Therapy Drugs for Leukemia by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Targeted Therapy Drugs for Leukemia by Country/Region, 2019, 2023 & 2030
2.2 Targeted Therapy Drugs for Leukemia Segment by Type
2.2.1 Monoclonal Antibodies
2.2.2 Small-Molecule Drugs
2.3 Targeted Therapy Drugs for Leukemia Sales by Type
2.3.1 Global Targeted Therapy Drugs for Leukemia Sales Market Share by Type (2019-2024)
2.3.2 Global Targeted Therapy Drugs for Leukemia Revenue and Market Share by Type (2019-2024)
2.3.3 Global Targeted Therapy Drugs for Leukemia Sale Price by Type (2019-2024)
2.4 Targeted Therapy Drugs for Leukemia Segment by Application
2.4.1 Acute Myeloid Leukemia (AML)
2.4.2 Chronic Myeloid Leukemia (CML)
2.4.3 Acute Lymphoblastic Leukemia (ALL)
2.4.4 Chronic Lymphocytic Leukemia (CLL)
2.5 Targeted Therapy Drugs for Leukemia Sales by Application
2.5.1 Global Targeted Therapy Drugs for Leukemia Sale Market Share by Application (2019-2024)
2.5.2 Global Targeted Therapy Drugs for Leukemia Revenue and Market Share by Application (2019-2024)
2.5.3 Global Targeted Therapy Drugs for Leukemia Sale Price by Application (2019-2024)
3 GLOBAL BY COMPANY
3.1 Global Targeted Therapy Drugs for Leukemia Breakdown Data by Company
3.1.1 Global Targeted Therapy Drugs for Leukemia Annual Sales by Company (2019-2024)
3.1.2 Global Targeted Therapy Drugs for Leukemia Sales Market Share by Company (2019-2024)
3.2 Global Targeted Therapy Drugs for Leukemia Annual Revenue by Company (2019-2024)
3.2.1 Global Targeted Therapy Drugs for Leukemia Revenue by Company (2019-2024)
3.2.2 Global Targeted Therapy Drugs for Leukemia Revenue Market Share by Company (2019-2024)
3.3 Global Targeted Therapy Drugs for Leukemia Sale Price by Company
3.4 Key Manufacturers Targeted Therapy Drugs for Leukemia Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Targeted Therapy Drugs for Leukemia Product Location Distribution
3.4.2 Players Targeted Therapy Drugs for Leukemia Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR TARGETED THERAPY DRUGS FOR LEUKEMIA BY GEOGRAPHIC REGION
4.1 World Historic Targeted Therapy Drugs for Leukemia Market Size by Geographic Region (2019-2024)
4.1.1 Global Targeted Therapy Drugs for Leukemia Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Targeted Therapy Drugs for Leukemia Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Targeted Therapy Drugs for Leukemia Market Size by Country/Region (2019-2024)
4.2.1 Global Targeted Therapy Drugs for Leukemia Annual Sales by Country/Region (2019-2024)
4.2.2 Global Targeted Therapy Drugs for Leukemia Annual Revenue by Country/Region (2019-2024)
4.3 Americas Targeted Therapy Drugs for Leukemia Sales Growth
4.4 APAC Targeted Therapy Drugs for Leukemia Sales Growth
4.5 Europe Targeted Therapy Drugs for Leukemia Sales Growth
4.6 Middle East & Africa Targeted Therapy Drugs for Leukemia Sales Growth
5 AMERICAS
5.1 Americas Targeted Therapy Drugs for Leukemia Sales by Country
5.1.1 Americas Targeted Therapy Drugs for Leukemia Sales by Country (2019-2024)
5.1.2 Americas Targeted Therapy Drugs for Leukemia Revenue by Country (2019-2024)
5.2 Americas Targeted Therapy Drugs for Leukemia Sales by Type (2019-2024)
5.3 Americas Targeted Therapy Drugs for Leukemia Sales by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Targeted Therapy Drugs for Leukemia Sales by Region
6.1.1 APAC Targeted Therapy Drugs for Leukemia Sales by Region (2019-2024)
6.1.2 APAC Targeted Therapy Drugs for Leukemia Revenue by Region (2019-2024)
6.2 APAC Targeted Therapy Drugs for Leukemia Sales by Type (2019-2024)
6.3 APAC Targeted Therapy Drugs for Leukemia Sales by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Targeted Therapy Drugs for Leukemia by Country
7.1.1 Europe Targeted Therapy Drugs for Leukemia Sales by Country (2019-2024)
7.1.2 Europe Targeted Therapy Drugs for Leukemia Revenue by Country (2019-2024)
7.2 Europe Targeted Therapy Drugs for Leukemia Sales by Type (2019-2024)
7.3 Europe Targeted Therapy Drugs for Leukemia Sales by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Targeted Therapy Drugs for Leukemia by Country
8.1.1 Middle East & Africa Targeted Therapy Drugs for Leukemia Sales by Country (2019-2024)
8.1.2 Middle East & Africa Targeted Therapy Drugs for Leukemia Revenue by Country (2019-2024)
8.2 Middle East & Africa Targeted Therapy Drugs for Leukemia Sales by Type (2019-2024)
8.3 Middle East & Africa Targeted Therapy Drugs for Leukemia Sales by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Targeted Therapy Drugs for Leukemia
10.3 Manufacturing Process Analysis of Targeted Therapy Drugs for Leukemia
10.4 Industry Chain Structure of Targeted Therapy Drugs for Leukemia
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Targeted Therapy Drugs for Leukemia Distributors
11.3 Targeted Therapy Drugs for Leukemia Customer
12 WORLD FORECAST REVIEW FOR TARGETED THERAPY DRUGS FOR LEUKEMIA BY GEOGRAPHIC REGION
12.1 Global Targeted Therapy Drugs for Leukemia Market Size Forecast by Region
12.1.1 Global Targeted Therapy Drugs for Leukemia Forecast by Region (2025-2030)
12.1.2 Global Targeted Therapy Drugs for Leukemia Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country (2025-2030)
12.3 APAC Forecast by Region (2025-2030)
12.4 Europe Forecast by Country (2025-2030)
12.5 Middle East & Africa Forecast by Country (2025-2030)
12.6 Global Targeted Therapy Drugs for Leukemia Forecast by Type (2025-2030)
12.7 Global Targeted Therapy Drugs for Leukemia Forecast by Application (2025-2030)
13 KEY PLAYERS ANALYSIS
13.1 Novartis Pharms
13.1.1 Novartis Pharms Company Information
13.1.2 Novartis Pharms Targeted Therapy Drugs for Leukemia Product Portfolios and Specifications
13.1.3 Novartis Pharms Targeted Therapy Drugs for Leukemia Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Novartis Pharms Main Business Overview
13.1.5 Novartis Pharms Latest Developments
13.2 Bristol-Myers Squibb
13.2.1 Bristol-Myers Squibb Company Information
13.2.2 Bristol-Myers Squibb Targeted Therapy Drugs for Leukemia Product Portfolios and Specifications
13.2.3 Bristol-Myers Squibb Targeted Therapy Drugs for Leukemia Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Bristol-Myers Squibb Main Business Overview
13.2.5 Bristol-Myers Squibb Latest Developments
13.3 IL-Yang Pharms
13.3.1 IL-Yang Pharms Company Information
13.3.2 IL-Yang Pharms Targeted Therapy Drugs for Leukemia Product Portfolios and Specifications
13.3.3 IL-Yang Pharms Targeted Therapy Drugs for Leukemia Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 IL-Yang Pharms Main Business Overview
13.3.5 IL-Yang Pharms Latest Developments
13.4 Pfizer
13.4.1 Pfizer Company Information
13.4.2 Pfizer Targeted Therapy Drugs for Leukemia Product Portfolios and Specifications
13.4.3 Pfizer Targeted Therapy Drugs for Leukemia Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Pfizer Main Business Overview
13.4.5 Pfizer Latest Developments
13.5 Takeda Oncology
13.5.1 Takeda Oncology Company Information
13.5.2 Takeda Oncology Targeted Therapy Drugs for Leukemia Product Portfolios and Specifications
13.5.3 Takeda Oncology Targeted Therapy Drugs for Leukemia Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Takeda Oncology Main Business Overview
13.5.5 Takeda Oncology Latest Developments
13.6 Johnson & Johnson
13.6.1 Johnson & Johnson Company Information
13.6.2 Johnson & Johnson Targeted Therapy Drugs for Leukemia Product Portfolios and Specifications
13.6.3 Johnson & Johnson Targeted Therapy Drugs for Leukemia Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Johnson & Johnson Main Business Overview
13.6.5 Johnson & Johnson Latest Developments
13.7 Gilead Sciences
13.7.1 Gilead Sciences Company Information
13.7.2 Gilead Sciences Targeted Therapy Drugs for Leukemia Product Portfolios and Specifications
13.7.3 Gilead Sciences Targeted Therapy Drugs for Leukemia Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Gilead Sciences Main Business Overview
13.7.5 Gilead Sciences Latest Developments
13.8 Abbvie
13.8.1 Abbvie Company Information
13.8.2 Abbvie Targeted Therapy Drugs for Leukemia Product Portfolios and Specifications
13.8.3 Abbvie Targeted Therapy Drugs for Leukemia Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Abbvie Main Business Overview
13.8.5 Abbvie Latest Developments
13.9 Genentech
13.9.1 Genentech Company Information
13.9.2 Genentech Targeted Therapy Drugs for Leukemia Product Portfolios and Specifications
13.9.3 Genentech Targeted Therapy Drugs for Leukemia Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Genentech Main Business Overview
13.9.5 Genentech Latest Developments
13.10 Sanofi
13.10.1 Sanofi Company Information
13.10.2 Sanofi Targeted Therapy Drugs for Leukemia Product Portfolios and Specifications
13.10.3 Sanofi Targeted Therapy Drugs for Leukemia Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 Sanofi Main Business Overview
13.10.5 Sanofi Latest Developments
13.11 Amgen
13.11.1 Amgen Company Information
13.11.2 Amgen Targeted Therapy Drugs for Leukemia Product Portfolios and Specifications
13.11.3 Amgen Targeted Therapy Drugs for Leukemia Sales, Revenue, Price and Gross Margin (2019-2024)
13.11.4 Amgen Main Business Overview
13.11.5 Amgen Latest Developments
13.12 Roche
13.12.1 Roche Company Information
13.12.2 Roche Targeted Therapy Drugs for Leukemia Product Portfolios and Specifications
13.12.3 Roche Targeted Therapy Drugs for Leukemia Sales, Revenue, Price and Gross Margin (2019-2024)
13.12.4 Roche Main Business Overview
13.12.5 Roche Latest Developments
13.13 GlaxoSmithKline
13.13.1 GlaxoSmithKline Company Information
13.13.2 GlaxoSmithKline Targeted Therapy Drugs for Leukemia Product Portfolios and Specifications
13.13.3 GlaxoSmithKline Targeted Therapy Drugs for Leukemia Sales, Revenue, Price and Gross Margin (2019-2024)
13.13.4 GlaxoSmithKline Main Business Overview
13.13.5 GlaxoSmithKline Latest Developments
13.14 AstraZeneca
13.14.1 AstraZeneca Company Information
13.14.2 AstraZeneca Targeted Therapy Drugs for Leukemia Product Portfolios and Specifications
13.14.3 AstraZeneca Targeted Therapy Drugs for Leukemia Sales, Revenue, Price and Gross Margin (2019-2024)
13.14.4 AstraZeneca Main Business Overview
13.14.5 AstraZeneca Latest Developments
13.15 BeiGene
13.15.1 BeiGene Company Information
13.15.2 BeiGene Targeted Therapy Drugs for Leukemia Product Portfolios and Specifications
13.15.3 BeiGene Targeted Therapy Drugs for Leukemia Sales, Revenue, Price and Gross Margin (2019-2024)
13.15.4 BeiGene Main Business Overview
13.15.5 BeiGene Latest Developments
13.16 Eli Lilly
13.16.1 Eli Lilly Company Information
13.16.2 Eli Lilly Targeted Therapy Drugs for Leukemia Product Portfolios and Specifications
13.16.3 Eli Lilly Targeted Therapy Drugs for Leukemia Sales, Revenue, Price and Gross Margin (2019-2024)
13.16.4 Eli Lilly Main Business Overview
13.16.5 Eli Lilly Latest Developments
13.17 Merck
13.17.1 Merck Company Information
13.17.2 Merck Targeted Therapy Drugs for Leukemia Product Portfolios and Specifications
13.17.3 Merck Targeted Therapy Drugs for Leukemia Sales, Revenue, Price and Gross Margin (2019-2024)
13.17.4 Merck Main Business Overview
13.17.5 Merck Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Targeted Therapy Drugs for Leukemia Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Targeted Therapy Drugs for Leukemia by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Targeted Therapy Drugs for Leukemia by Country/Region, 2019, 2023 & 2030
2.2 Targeted Therapy Drugs for Leukemia Segment by Type
2.2.1 Monoclonal Antibodies
2.2.2 Small-Molecule Drugs
2.3 Targeted Therapy Drugs for Leukemia Sales by Type
2.3.1 Global Targeted Therapy Drugs for Leukemia Sales Market Share by Type (2019-2024)
2.3.2 Global Targeted Therapy Drugs for Leukemia Revenue and Market Share by Type (2019-2024)
2.3.3 Global Targeted Therapy Drugs for Leukemia Sale Price by Type (2019-2024)
2.4 Targeted Therapy Drugs for Leukemia Segment by Application
2.4.1 Acute Myeloid Leukemia (AML)
2.4.2 Chronic Myeloid Leukemia (CML)
2.4.3 Acute Lymphoblastic Leukemia (ALL)
2.4.4 Chronic Lymphocytic Leukemia (CLL)
2.5 Targeted Therapy Drugs for Leukemia Sales by Application
2.5.1 Global Targeted Therapy Drugs for Leukemia Sale Market Share by Application (2019-2024)
2.5.2 Global Targeted Therapy Drugs for Leukemia Revenue and Market Share by Application (2019-2024)
2.5.3 Global Targeted Therapy Drugs for Leukemia Sale Price by Application (2019-2024)
3 GLOBAL BY COMPANY
3.1 Global Targeted Therapy Drugs for Leukemia Breakdown Data by Company
3.1.1 Global Targeted Therapy Drugs for Leukemia Annual Sales by Company (2019-2024)
3.1.2 Global Targeted Therapy Drugs for Leukemia Sales Market Share by Company (2019-2024)
3.2 Global Targeted Therapy Drugs for Leukemia Annual Revenue by Company (2019-2024)
3.2.1 Global Targeted Therapy Drugs for Leukemia Revenue by Company (2019-2024)
3.2.2 Global Targeted Therapy Drugs for Leukemia Revenue Market Share by Company (2019-2024)
3.3 Global Targeted Therapy Drugs for Leukemia Sale Price by Company
3.4 Key Manufacturers Targeted Therapy Drugs for Leukemia Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Targeted Therapy Drugs for Leukemia Product Location Distribution
3.4.2 Players Targeted Therapy Drugs for Leukemia Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR TARGETED THERAPY DRUGS FOR LEUKEMIA BY GEOGRAPHIC REGION
4.1 World Historic Targeted Therapy Drugs for Leukemia Market Size by Geographic Region (2019-2024)
4.1.1 Global Targeted Therapy Drugs for Leukemia Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Targeted Therapy Drugs for Leukemia Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Targeted Therapy Drugs for Leukemia Market Size by Country/Region (2019-2024)
4.2.1 Global Targeted Therapy Drugs for Leukemia Annual Sales by Country/Region (2019-2024)
4.2.2 Global Targeted Therapy Drugs for Leukemia Annual Revenue by Country/Region (2019-2024)
4.3 Americas Targeted Therapy Drugs for Leukemia Sales Growth
4.4 APAC Targeted Therapy Drugs for Leukemia Sales Growth
4.5 Europe Targeted Therapy Drugs for Leukemia Sales Growth
4.6 Middle East & Africa Targeted Therapy Drugs for Leukemia Sales Growth
5 AMERICAS
5.1 Americas Targeted Therapy Drugs for Leukemia Sales by Country
5.1.1 Americas Targeted Therapy Drugs for Leukemia Sales by Country (2019-2024)
5.1.2 Americas Targeted Therapy Drugs for Leukemia Revenue by Country (2019-2024)
5.2 Americas Targeted Therapy Drugs for Leukemia Sales by Type (2019-2024)
5.3 Americas Targeted Therapy Drugs for Leukemia Sales by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Targeted Therapy Drugs for Leukemia Sales by Region
6.1.1 APAC Targeted Therapy Drugs for Leukemia Sales by Region (2019-2024)
6.1.2 APAC Targeted Therapy Drugs for Leukemia Revenue by Region (2019-2024)
6.2 APAC Targeted Therapy Drugs for Leukemia Sales by Type (2019-2024)
6.3 APAC Targeted Therapy Drugs for Leukemia Sales by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Targeted Therapy Drugs for Leukemia by Country
7.1.1 Europe Targeted Therapy Drugs for Leukemia Sales by Country (2019-2024)
7.1.2 Europe Targeted Therapy Drugs for Leukemia Revenue by Country (2019-2024)
7.2 Europe Targeted Therapy Drugs for Leukemia Sales by Type (2019-2024)
7.3 Europe Targeted Therapy Drugs for Leukemia Sales by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Targeted Therapy Drugs for Leukemia by Country
8.1.1 Middle East & Africa Targeted Therapy Drugs for Leukemia Sales by Country (2019-2024)
8.1.2 Middle East & Africa Targeted Therapy Drugs for Leukemia Revenue by Country (2019-2024)
8.2 Middle East & Africa Targeted Therapy Drugs for Leukemia Sales by Type (2019-2024)
8.3 Middle East & Africa Targeted Therapy Drugs for Leukemia Sales by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Targeted Therapy Drugs for Leukemia
10.3 Manufacturing Process Analysis of Targeted Therapy Drugs for Leukemia
10.4 Industry Chain Structure of Targeted Therapy Drugs for Leukemia
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Targeted Therapy Drugs for Leukemia Distributors
11.3 Targeted Therapy Drugs for Leukemia Customer
12 WORLD FORECAST REVIEW FOR TARGETED THERAPY DRUGS FOR LEUKEMIA BY GEOGRAPHIC REGION
12.1 Global Targeted Therapy Drugs for Leukemia Market Size Forecast by Region
12.1.1 Global Targeted Therapy Drugs for Leukemia Forecast by Region (2025-2030)
12.1.2 Global Targeted Therapy Drugs for Leukemia Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country (2025-2030)
12.3 APAC Forecast by Region (2025-2030)
12.4 Europe Forecast by Country (2025-2030)
12.5 Middle East & Africa Forecast by Country (2025-2030)
12.6 Global Targeted Therapy Drugs for Leukemia Forecast by Type (2025-2030)
12.7 Global Targeted Therapy Drugs for Leukemia Forecast by Application (2025-2030)
13 KEY PLAYERS ANALYSIS
13.1 Novartis Pharms
13.1.1 Novartis Pharms Company Information
13.1.2 Novartis Pharms Targeted Therapy Drugs for Leukemia Product Portfolios and Specifications
13.1.3 Novartis Pharms Targeted Therapy Drugs for Leukemia Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Novartis Pharms Main Business Overview
13.1.5 Novartis Pharms Latest Developments
13.2 Bristol-Myers Squibb
13.2.1 Bristol-Myers Squibb Company Information
13.2.2 Bristol-Myers Squibb Targeted Therapy Drugs for Leukemia Product Portfolios and Specifications
13.2.3 Bristol-Myers Squibb Targeted Therapy Drugs for Leukemia Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Bristol-Myers Squibb Main Business Overview
13.2.5 Bristol-Myers Squibb Latest Developments
13.3 IL-Yang Pharms
13.3.1 IL-Yang Pharms Company Information
13.3.2 IL-Yang Pharms Targeted Therapy Drugs for Leukemia Product Portfolios and Specifications
13.3.3 IL-Yang Pharms Targeted Therapy Drugs for Leukemia Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 IL-Yang Pharms Main Business Overview
13.3.5 IL-Yang Pharms Latest Developments
13.4 Pfizer
13.4.1 Pfizer Company Information
13.4.2 Pfizer Targeted Therapy Drugs for Leukemia Product Portfolios and Specifications
13.4.3 Pfizer Targeted Therapy Drugs for Leukemia Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Pfizer Main Business Overview
13.4.5 Pfizer Latest Developments
13.5 Takeda Oncology
13.5.1 Takeda Oncology Company Information
13.5.2 Takeda Oncology Targeted Therapy Drugs for Leukemia Product Portfolios and Specifications
13.5.3 Takeda Oncology Targeted Therapy Drugs for Leukemia Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Takeda Oncology Main Business Overview
13.5.5 Takeda Oncology Latest Developments
13.6 Johnson & Johnson
13.6.1 Johnson & Johnson Company Information
13.6.2 Johnson & Johnson Targeted Therapy Drugs for Leukemia Product Portfolios and Specifications
13.6.3 Johnson & Johnson Targeted Therapy Drugs for Leukemia Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Johnson & Johnson Main Business Overview
13.6.5 Johnson & Johnson Latest Developments
13.7 Gilead Sciences
13.7.1 Gilead Sciences Company Information
13.7.2 Gilead Sciences Targeted Therapy Drugs for Leukemia Product Portfolios and Specifications
13.7.3 Gilead Sciences Targeted Therapy Drugs for Leukemia Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Gilead Sciences Main Business Overview
13.7.5 Gilead Sciences Latest Developments
13.8 Abbvie
13.8.1 Abbvie Company Information
13.8.2 Abbvie Targeted Therapy Drugs for Leukemia Product Portfolios and Specifications
13.8.3 Abbvie Targeted Therapy Drugs for Leukemia Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Abbvie Main Business Overview
13.8.5 Abbvie Latest Developments
13.9 Genentech
13.9.1 Genentech Company Information
13.9.2 Genentech Targeted Therapy Drugs for Leukemia Product Portfolios and Specifications
13.9.3 Genentech Targeted Therapy Drugs for Leukemia Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Genentech Main Business Overview
13.9.5 Genentech Latest Developments
13.10 Sanofi
13.10.1 Sanofi Company Information
13.10.2 Sanofi Targeted Therapy Drugs for Leukemia Product Portfolios and Specifications
13.10.3 Sanofi Targeted Therapy Drugs for Leukemia Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 Sanofi Main Business Overview
13.10.5 Sanofi Latest Developments
13.11 Amgen
13.11.1 Amgen Company Information
13.11.2 Amgen Targeted Therapy Drugs for Leukemia Product Portfolios and Specifications
13.11.3 Amgen Targeted Therapy Drugs for Leukemia Sales, Revenue, Price and Gross Margin (2019-2024)
13.11.4 Amgen Main Business Overview
13.11.5 Amgen Latest Developments
13.12 Roche
13.12.1 Roche Company Information
13.12.2 Roche Targeted Therapy Drugs for Leukemia Product Portfolios and Specifications
13.12.3 Roche Targeted Therapy Drugs for Leukemia Sales, Revenue, Price and Gross Margin (2019-2024)
13.12.4 Roche Main Business Overview
13.12.5 Roche Latest Developments
13.13 GlaxoSmithKline
13.13.1 GlaxoSmithKline Company Information
13.13.2 GlaxoSmithKline Targeted Therapy Drugs for Leukemia Product Portfolios and Specifications
13.13.3 GlaxoSmithKline Targeted Therapy Drugs for Leukemia Sales, Revenue, Price and Gross Margin (2019-2024)
13.13.4 GlaxoSmithKline Main Business Overview
13.13.5 GlaxoSmithKline Latest Developments
13.14 AstraZeneca
13.14.1 AstraZeneca Company Information
13.14.2 AstraZeneca Targeted Therapy Drugs for Leukemia Product Portfolios and Specifications
13.14.3 AstraZeneca Targeted Therapy Drugs for Leukemia Sales, Revenue, Price and Gross Margin (2019-2024)
13.14.4 AstraZeneca Main Business Overview
13.14.5 AstraZeneca Latest Developments
13.15 BeiGene
13.15.1 BeiGene Company Information
13.15.2 BeiGene Targeted Therapy Drugs for Leukemia Product Portfolios and Specifications
13.15.3 BeiGene Targeted Therapy Drugs for Leukemia Sales, Revenue, Price and Gross Margin (2019-2024)
13.15.4 BeiGene Main Business Overview
13.15.5 BeiGene Latest Developments
13.16 Eli Lilly
13.16.1 Eli Lilly Company Information
13.16.2 Eli Lilly Targeted Therapy Drugs for Leukemia Product Portfolios and Specifications
13.16.3 Eli Lilly Targeted Therapy Drugs for Leukemia Sales, Revenue, Price and Gross Margin (2019-2024)
13.16.4 Eli Lilly Main Business Overview
13.16.5 Eli Lilly Latest Developments
13.17 Merck
13.17.1 Merck Company Information
13.17.2 Merck Targeted Therapy Drugs for Leukemia Product Portfolios and Specifications
13.17.3 Merck Targeted Therapy Drugs for Leukemia Sales, Revenue, Price and Gross Margin (2019-2024)
13.17.4 Merck Main Business Overview
13.17.5 Merck Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Targeted Therapy Drugs for Leukemia Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions)
Table 2. Targeted Therapy Drugs for Leukemia Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of Monoclonal Antibodies
Table 4. Major Players of Small-Molecule Drugs
Table 5. Global Targeted Therapy Drugs for Leukemia Sales by Type (2019-2024) & (Units)
Table 6. Global Targeted Therapy Drugs for Leukemia Sales Market Share by Type (2019-2024)
Table 7. Global Targeted Therapy Drugs for Leukemia Revenue by Type (2019-2024) & ($ million)
Table 8. Global Targeted Therapy Drugs for Leukemia Revenue Market Share by Type (2019-2024)
Table 9. Global Targeted Therapy Drugs for Leukemia Sale Price by Type (2019-2024) & (US$/Unit)
Table 10. Global Targeted Therapy Drugs for Leukemia Sale by Application (2019-2024) & (Units)
Table 11. Global Targeted Therapy Drugs for Leukemia Sale Market Share by Application (2019-2024)
Table 12. Global Targeted Therapy Drugs for Leukemia Revenue by Application (2019-2024) & ($ million)
Table 13. Global Targeted Therapy Drugs for Leukemia Revenue Market Share by Application (2019-2024)
Table 14. Global Targeted Therapy Drugs for Leukemia Sale Price by Application (2019-2024) & (US$/Unit)
Table 15. Global Targeted Therapy Drugs for Leukemia Sales by Company (2019-2024) & (Units)
Table 16. Global Targeted Therapy Drugs for Leukemia Sales Market Share by Company (2019-2024)
Table 17. Global Targeted Therapy Drugs for Leukemia Revenue by Company (2019-2024) & ($ millions)
Table 18. Global Targeted Therapy Drugs for Leukemia Revenue Market Share by Company (2019-2024)
Table 19. Global Targeted Therapy Drugs for Leukemia Sale Price by Company (2019-2024) & (US$/Unit)
Table 20. Key Manufacturers Targeted Therapy Drugs for Leukemia Producing Area Distribution and Sales Area
Table 21. Players Targeted Therapy Drugs for Leukemia Products Offered
Table 22. Targeted Therapy Drugs for Leukemia Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
Table 23. New Products and Potential Entrants
Table 24. Market M&A Activity & Strategy
Table 25. Global Targeted Therapy Drugs for Leukemia Sales by Geographic Region (2019-2024) & (Units)
Table 26. Global Targeted Therapy Drugs for Leukemia Sales Market Share Geographic Region (2019-2024)
Table 27. Global Targeted Therapy Drugs for Leukemia Revenue by Geographic Region (2019-2024) & ($ millions)
Table 28. Global Targeted Therapy Drugs for Leukemia Revenue Market Share by Geographic Region (2019-2024)
Table 29. Global Targeted Therapy Drugs for Leukemia Sales by Country/Region (2019-2024) & (Units)
Table 30. Global Targeted Therapy Drugs for Leukemia Sales Market Share by Country/Region (2019-2024)
Table 31. Global Targeted Therapy Drugs for Leukemia Revenue by Country/Region (2019-2024) & ($ millions)
Table 32. Global Targeted Therapy Drugs for Leukemia Revenue Market Share by Country/Region (2019-2024)
Table 33. Americas Targeted Therapy Drugs for Leukemia Sales by Country (2019-2024) & (Units)
Table 34. Americas Targeted Therapy Drugs for Leukemia Sales Market Share by Country (2019-2024)
Table 35. Americas Targeted Therapy Drugs for Leukemia Revenue by Country (2019-2024) & ($ millions)
Table 36. Americas Targeted Therapy Drugs for Leukemia Sales by Type (2019-2024) & (Units)
Table 37. Americas Targeted Therapy Drugs for Leukemia Sales by Application (2019-2024) & (Units)
Table 38. APAC Targeted Therapy Drugs for Leukemia Sales by Region (2019-2024) & (Units)
Table 39. APAC Targeted Therapy Drugs for Leukemia Sales Market Share by Region (2019-2024)
Table 40. APAC Targeted Therapy Drugs for Leukemia Revenue by Region (2019-2024) & ($ millions)
Table 41. APAC Targeted Therapy Drugs for Leukemia Sales by Type (2019-2024) & (Units)
Table 42. APAC Targeted Therapy Drugs for Leukemia Sales by Application (2019-2024) & (Units)
Table 43. Europe Targeted Therapy Drugs for Leukemia Sales by Country (2019-2024) & (Units)
Table 44. Europe Targeted Therapy Drugs for Leukemia Revenue by Country (2019-2024) & ($ millions)
Table 45. Europe Targeted Therapy Drugs for Leukemia Sales by Type (2019-2024) & (Units)
Table 46. Europe Targeted Therapy Drugs for Leukemia Sales by Application (2019-2024) & (Units)
Table 47. Middle East & Africa Targeted Therapy Drugs for Leukemia Sales by Country (2019-2024) & (Units)
Table 48. Middle East & Africa Targeted Therapy Drugs for Leukemia Revenue Market Share by Country (2019-2024)
Table 49. Middle East & Africa Targeted Therapy Drugs for Leukemia Sales by Type (2019-2024) & (Units)
Table 50. Middle East & Africa Targeted Therapy Drugs for Leukemia Sales by Application (2019-2024) & (Units)
Table 51. Key Market Drivers & Growth Opportunities of Targeted Therapy Drugs for Leukemia
Table 52. Key Market Challenges & Risks of Targeted Therapy Drugs for Leukemia
Table 53. Key Industry Trends of Targeted Therapy Drugs for Leukemia
Table 54. Targeted Therapy Drugs for Leukemia Raw Material
Table 55. Key Suppliers of Raw Materials
Table 56. Targeted Therapy Drugs for Leukemia Distributors List
Table 57. Targeted Therapy Drugs for Leukemia Customer List
Table 58. Global Targeted Therapy Drugs for Leukemia Sales Forecast by Region (2025-2030) & (Units)
Table 59. Global Targeted Therapy Drugs for Leukemia Revenue Forecast by Region (2025-2030) & ($ millions)
Table 60. Americas Targeted Therapy Drugs for Leukemia Sales Forecast by Country (2025-2030) & (Units)
Table 61. Americas Targeted Therapy Drugs for Leukemia Annual Revenue Forecast by Country (2025-2030) & ($ millions)
Table 62. APAC Targeted Therapy Drugs for Leukemia Sales Forecast by Region (2025-2030) & (Units)
Table 63. APAC Targeted Therapy Drugs for Leukemia Annual Revenue Forecast by Region (2025-2030) & ($ millions)
Table 64. Europe Targeted Therapy Drugs for Leukemia Sales Forecast by Country (2025-2030) & (Units)
Table 65. Europe Targeted Therapy Drugs for Leukemia Revenue Forecast by Country (2025-2030) & ($ millions)
Table 66. Middle East & Africa Targeted Therapy Drugs for Leukemia Sales Forecast by Country (2025-2030) & (Units)
Table 67. Middle East & Africa Targeted Therapy Drugs for Leukemia Revenue Forecast by Country (2025-2030) & ($ millions)
Table 68. Global Targeted Therapy Drugs for Leukemia Sales Forecast by Type (2025-2030) & (Units)
Table 69. Global Targeted Therapy Drugs for Leukemia Revenue Forecast by Type (2025-2030) & ($ millions)
Table 70. Global Targeted Therapy Drugs for Leukemia Sales Forecast by Application (2025-2030) & (Units)
Table 71. Global Targeted Therapy Drugs for Leukemia Revenue Forecast by Application (2025-2030) & ($ millions)
Table 72. Novartis Pharms Basic Information, Targeted Therapy Drugs for Leukemia Manufacturing Base, Sales Area and Its Competitors
Table 73. Novartis Pharms Targeted Therapy Drugs for Leukemia Product Portfolios and Specifications
Table 74. Novartis Pharms Targeted Therapy Drugs for Leukemia Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 75. Novartis Pharms Main Business
Table 76. Novartis Pharms Latest Developments
Table 77. Bristol-Myers Squibb Basic Information, Targeted Therapy Drugs for Leukemia Manufacturing Base, Sales Area and Its Competitors
Table 78. Bristol-Myers Squibb Targeted Therapy Drugs for Leukemia Product Portfolios and Specifications
Table 79. Bristol-Myers Squibb Targeted Therapy Drugs for Leukemia Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 80. Bristol-Myers Squibb Main Business
Table 81. Bristol-Myers Squibb Latest Developments
Table 82. IL-Yang Pharms Basic Information, Targeted Therapy Drugs for Leukemia Manufacturing Base, Sales Area and Its Competitors
Table 83. IL-Yang Pharms Targeted Therapy Drugs for Leukemia Product Portfolios and Specifications
Table 84. IL-Yang Pharms Targeted Therapy Drugs for Leukemia Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 85. IL-Yang Pharms Main Business
Table 86. IL-Yang Pharms Latest Developments
Table 87. Pfizer Basic Information, Targeted Therapy Drugs for Leukemia Manufacturing Base, Sales Area and Its Competitors
Table 88. Pfizer Targeted Therapy Drugs for Leukemia Product Portfolios and Specifications
Table 89. Pfizer Targeted Therapy Drugs for Leukemia Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 90. Pfizer Main Business
Table 91. Pfizer Latest Developments
Table 92. Takeda Oncology Basic Information, Targeted Therapy Drugs for Leukemia Manufacturing Base, Sales Area and Its Competitors
Table 93. Takeda Oncology Targeted Therapy Drugs for Leukemia Product Portfolios and Specifications
Table 94. Takeda Oncology Targeted Therapy Drugs for Leukemia Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 95. Takeda Oncology Main Business
Table 96. Takeda Oncology Latest Developments
Table 97. Johnson & Johnson Basic Information, Targeted Therapy Drugs for Leukemia Manufacturing Base, Sales Area and Its Competitors
Table 98. Johnson & Johnson Targeted Therapy Drugs for Leukemia Product Portfolios and Specifications
Table 99. Johnson & Johnson Targeted Therapy Drugs for Leukemia Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 100. Johnson & Johnson Main Business
Table 101. Johnson & Johnson Latest Developments
Table 102. Gilead Sciences Basic Information, Targeted Therapy Drugs for Leukemia Manufacturing Base, Sales Area and Its Competitors
Table 103. Gilead Sciences Targeted Therapy Drugs for Leukemia Product Portfolios and Specifications
Table 104. Gilead Sciences Targeted Therapy Drugs for Leukemia Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 105. Gilead Sciences Main Business
Table 106. Gilead Sciences Latest Developments
Table 107. Abbvie Basic Information, Targeted Therapy Drugs for Leukemia Manufacturing Base, Sales Area and Its Competitors
Table 108. Abbvie Targeted Therapy Drugs for Leukemia Product Portfolios and Specifications
Table 109. Abbvie Targeted Therapy Drugs for Leukemia Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 110. Abbvie Main Business
Table 111. Abbvie Latest Developments
Table 112. Genentech Basic Information, Targeted Therapy Drugs for Leukemia Manufacturing Base, Sales Area and Its Competitors
Table 113. Genentech Targeted Therapy Drugs for Leukemia Product Portfolios and Specifications
Table 114. Genentech Targeted Therapy Drugs for Leukemia Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 115. Genentech Main Business
Table 116. Genentech Latest Developments
Table 117. Sanofi Basic Information, Targeted Therapy Drugs for Leukemia Manufacturing Base, Sales Area and Its Competitors
Table 118. Sanofi Targeted Therapy Drugs for Leukemia Product Portfolios and Specifications
Table 119. Sanofi Targeted Therapy Drugs for Leukemia Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 120. Sanofi Main Business
Table 121. Sanofi Latest Developments
Table 122. Amgen Basic Information, Targeted Therapy Drugs for Leukemia Manufacturing Base, Sales Area and Its Competitors
Table 123. Amgen Targeted Therapy Drugs for Leukemia Product Portfolios and Specifications
Table 124. Amgen Targeted Therapy Drugs for Leukemia Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 125. Amgen Main Business
Table 126. Amgen Latest Developments
Table 127. Roche Basic Information, Targeted Therapy Drugs for Leukemia Manufacturing Base, Sales Area and Its Competitors
Table 128. Roche Targeted Therapy Drugs for Leukemia Product Portfolios and Specifications
Table 129. Roche Targeted Therapy Drugs for Leukemia Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 130. Roche Main Business
Table 131. Roche Latest Developments
Table 132. GlaxoSmithKline Basic Information, Targeted Therapy Drugs for Leukemia Manufacturing Base, Sales Area and Its Competitors
Table 133. GlaxoSmithKline Targeted Therapy Drugs for Leukemia Product Portfolios and Specifications
Table 134. GlaxoSmithKline Targeted Therapy Drugs for Leukemia Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 135. GlaxoSmithKline Main Business
Table 136. GlaxoSmithKline Latest Developments
Table 137. AstraZeneca Basic Information, Targeted Therapy Drugs for Leukemia Manufacturing Base, Sales Area and Its Competitors
Table 138. AstraZeneca Targeted Therapy Drugs for Leukemia Product Portfolios and Specifications
Table 139. AstraZeneca Targeted Therapy Drugs for Leukemia Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 140. AstraZeneca Main Business
Table 141. AstraZeneca Latest Developments
Table 142. BeiGene Basic Information, Targeted Therapy Drugs for Leukemia Manufacturing Base, Sales Area and Its Competitors
Table 143. BeiGene Targeted Therapy Drugs for Leukemia Product Portfolios and Specifications
Table 144. BeiGene Targeted Therapy Drugs for Leukemia Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 145. BeiGene Main Business
Table 146. BeiGene Latest Developments
Table 147. Eli Lilly Basic Information, Targeted Therapy Drugs for Leukemia Manufacturing Base, Sales Area and Its Competitors
Table 148. Eli Lilly Targeted Therapy Drugs for Leukemia Product Portfolios and Specifications
Table 149. Eli Lilly Targeted Therapy Drugs for Leukemia Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 150. Eli Lilly Main Business
Table 151. Eli Lilly Latest Developments
Table 152. Merck Basic Information, Targeted Therapy Drugs for Leukemia Manufacturing Base, Sales Area and Its Competitors
Table 153. Merck Targeted Therapy Drugs for Leukemia Product Portfolios and Specifications
Table 154. Merck Targeted Therapy Drugs for Leukemia Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 155. Merck Main Business
Table 156. Merck Latest Developments
Table 1. Targeted Therapy Drugs for Leukemia Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions)
Table 2. Targeted Therapy Drugs for Leukemia Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of Monoclonal Antibodies
Table 4. Major Players of Small-Molecule Drugs
Table 5. Global Targeted Therapy Drugs for Leukemia Sales by Type (2019-2024) & (Units)
Table 6. Global Targeted Therapy Drugs for Leukemia Sales Market Share by Type (2019-2024)
Table 7. Global Targeted Therapy Drugs for Leukemia Revenue by Type (2019-2024) & ($ million)
Table 8. Global Targeted Therapy Drugs for Leukemia Revenue Market Share by Type (2019-2024)
Table 9. Global Targeted Therapy Drugs for Leukemia Sale Price by Type (2019-2024) & (US$/Unit)
Table 10. Global Targeted Therapy Drugs for Leukemia Sale by Application (2019-2024) & (Units)
Table 11. Global Targeted Therapy Drugs for Leukemia Sale Market Share by Application (2019-2024)
Table 12. Global Targeted Therapy Drugs for Leukemia Revenue by Application (2019-2024) & ($ million)
Table 13. Global Targeted Therapy Drugs for Leukemia Revenue Market Share by Application (2019-2024)
Table 14. Global Targeted Therapy Drugs for Leukemia Sale Price by Application (2019-2024) & (US$/Unit)
Table 15. Global Targeted Therapy Drugs for Leukemia Sales by Company (2019-2024) & (Units)
Table 16. Global Targeted Therapy Drugs for Leukemia Sales Market Share by Company (2019-2024)
Table 17. Global Targeted Therapy Drugs for Leukemia Revenue by Company (2019-2024) & ($ millions)
Table 18. Global Targeted Therapy Drugs for Leukemia Revenue Market Share by Company (2019-2024)
Table 19. Global Targeted Therapy Drugs for Leukemia Sale Price by Company (2019-2024) & (US$/Unit)
Table 20. Key Manufacturers Targeted Therapy Drugs for Leukemia Producing Area Distribution and Sales Area
Table 21. Players Targeted Therapy Drugs for Leukemia Products Offered
Table 22. Targeted Therapy Drugs for Leukemia Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
Table 23. New Products and Potential Entrants
Table 24. Market M&A Activity & Strategy
Table 25. Global Targeted Therapy Drugs for Leukemia Sales by Geographic Region (2019-2024) & (Units)
Table 26. Global Targeted Therapy Drugs for Leukemia Sales Market Share Geographic Region (2019-2024)
Table 27. Global Targeted Therapy Drugs for Leukemia Revenue by Geographic Region (2019-2024) & ($ millions)
Table 28. Global Targeted Therapy Drugs for Leukemia Revenue Market Share by Geographic Region (2019-2024)
Table 29. Global Targeted Therapy Drugs for Leukemia Sales by Country/Region (2019-2024) & (Units)
Table 30. Global Targeted Therapy Drugs for Leukemia Sales Market Share by Country/Region (2019-2024)
Table 31. Global Targeted Therapy Drugs for Leukemia Revenue by Country/Region (2019-2024) & ($ millions)
Table 32. Global Targeted Therapy Drugs for Leukemia Revenue Market Share by Country/Region (2019-2024)
Table 33. Americas Targeted Therapy Drugs for Leukemia Sales by Country (2019-2024) & (Units)
Table 34. Americas Targeted Therapy Drugs for Leukemia Sales Market Share by Country (2019-2024)
Table 35. Americas Targeted Therapy Drugs for Leukemia Revenue by Country (2019-2024) & ($ millions)
Table 36. Americas Targeted Therapy Drugs for Leukemia Sales by Type (2019-2024) & (Units)
Table 37. Americas Targeted Therapy Drugs for Leukemia Sales by Application (2019-2024) & (Units)
Table 38. APAC Targeted Therapy Drugs for Leukemia Sales by Region (2019-2024) & (Units)
Table 39. APAC Targeted Therapy Drugs for Leukemia Sales Market Share by Region (2019-2024)
Table 40. APAC Targeted Therapy Drugs for Leukemia Revenue by Region (2019-2024) & ($ millions)
Table 41. APAC Targeted Therapy Drugs for Leukemia Sales by Type (2019-2024) & (Units)
Table 42. APAC Targeted Therapy Drugs for Leukemia Sales by Application (2019-2024) & (Units)
Table 43. Europe Targeted Therapy Drugs for Leukemia Sales by Country (2019-2024) & (Units)
Table 44. Europe Targeted Therapy Drugs for Leukemia Revenue by Country (2019-2024) & ($ millions)
Table 45. Europe Targeted Therapy Drugs for Leukemia Sales by Type (2019-2024) & (Units)
Table 46. Europe Targeted Therapy Drugs for Leukemia Sales by Application (2019-2024) & (Units)
Table 47. Middle East & Africa Targeted Therapy Drugs for Leukemia Sales by Country (2019-2024) & (Units)
Table 48. Middle East & Africa Targeted Therapy Drugs for Leukemia Revenue Market Share by Country (2019-2024)
Table 49. Middle East & Africa Targeted Therapy Drugs for Leukemia Sales by Type (2019-2024) & (Units)
Table 50. Middle East & Africa Targeted Therapy Drugs for Leukemia Sales by Application (2019-2024) & (Units)
Table 51. Key Market Drivers & Growth Opportunities of Targeted Therapy Drugs for Leukemia
Table 52. Key Market Challenges & Risks of Targeted Therapy Drugs for Leukemia
Table 53. Key Industry Trends of Targeted Therapy Drugs for Leukemia
Table 54. Targeted Therapy Drugs for Leukemia Raw Material
Table 55. Key Suppliers of Raw Materials
Table 56. Targeted Therapy Drugs for Leukemia Distributors List
Table 57. Targeted Therapy Drugs for Leukemia Customer List
Table 58. Global Targeted Therapy Drugs for Leukemia Sales Forecast by Region (2025-2030) & (Units)
Table 59. Global Targeted Therapy Drugs for Leukemia Revenue Forecast by Region (2025-2030) & ($ millions)
Table 60. Americas Targeted Therapy Drugs for Leukemia Sales Forecast by Country (2025-2030) & (Units)
Table 61. Americas Targeted Therapy Drugs for Leukemia Annual Revenue Forecast by Country (2025-2030) & ($ millions)
Table 62. APAC Targeted Therapy Drugs for Leukemia Sales Forecast by Region (2025-2030) & (Units)
Table 63. APAC Targeted Therapy Drugs for Leukemia Annual Revenue Forecast by Region (2025-2030) & ($ millions)
Table 64. Europe Targeted Therapy Drugs for Leukemia Sales Forecast by Country (2025-2030) & (Units)
Table 65. Europe Targeted Therapy Drugs for Leukemia Revenue Forecast by Country (2025-2030) & ($ millions)
Table 66. Middle East & Africa Targeted Therapy Drugs for Leukemia Sales Forecast by Country (2025-2030) & (Units)
Table 67. Middle East & Africa Targeted Therapy Drugs for Leukemia Revenue Forecast by Country (2025-2030) & ($ millions)
Table 68. Global Targeted Therapy Drugs for Leukemia Sales Forecast by Type (2025-2030) & (Units)
Table 69. Global Targeted Therapy Drugs for Leukemia Revenue Forecast by Type (2025-2030) & ($ millions)
Table 70. Global Targeted Therapy Drugs for Leukemia Sales Forecast by Application (2025-2030) & (Units)
Table 71. Global Targeted Therapy Drugs for Leukemia Revenue Forecast by Application (2025-2030) & ($ millions)
Table 72. Novartis Pharms Basic Information, Targeted Therapy Drugs for Leukemia Manufacturing Base, Sales Area and Its Competitors
Table 73. Novartis Pharms Targeted Therapy Drugs for Leukemia Product Portfolios and Specifications
Table 74. Novartis Pharms Targeted Therapy Drugs for Leukemia Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 75. Novartis Pharms Main Business
Table 76. Novartis Pharms Latest Developments
Table 77. Bristol-Myers Squibb Basic Information, Targeted Therapy Drugs for Leukemia Manufacturing Base, Sales Area and Its Competitors
Table 78. Bristol-Myers Squibb Targeted Therapy Drugs for Leukemia Product Portfolios and Specifications
Table 79. Bristol-Myers Squibb Targeted Therapy Drugs for Leukemia Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 80. Bristol-Myers Squibb Main Business
Table 81. Bristol-Myers Squibb Latest Developments
Table 82. IL-Yang Pharms Basic Information, Targeted Therapy Drugs for Leukemia Manufacturing Base, Sales Area and Its Competitors
Table 83. IL-Yang Pharms Targeted Therapy Drugs for Leukemia Product Portfolios and Specifications
Table 84. IL-Yang Pharms Targeted Therapy Drugs for Leukemia Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 85. IL-Yang Pharms Main Business
Table 86. IL-Yang Pharms Latest Developments
Table 87. Pfizer Basic Information, Targeted Therapy Drugs for Leukemia Manufacturing Base, Sales Area and Its Competitors
Table 88. Pfizer Targeted Therapy Drugs for Leukemia Product Portfolios and Specifications
Table 89. Pfizer Targeted Therapy Drugs for Leukemia Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 90. Pfizer Main Business
Table 91. Pfizer Latest Developments
Table 92. Takeda Oncology Basic Information, Targeted Therapy Drugs for Leukemia Manufacturing Base, Sales Area and Its Competitors
Table 93. Takeda Oncology Targeted Therapy Drugs for Leukemia Product Portfolios and Specifications
Table 94. Takeda Oncology Targeted Therapy Drugs for Leukemia Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 95. Takeda Oncology Main Business
Table 96. Takeda Oncology Latest Developments
Table 97. Johnson & Johnson Basic Information, Targeted Therapy Drugs for Leukemia Manufacturing Base, Sales Area and Its Competitors
Table 98. Johnson & Johnson Targeted Therapy Drugs for Leukemia Product Portfolios and Specifications
Table 99. Johnson & Johnson Targeted Therapy Drugs for Leukemia Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 100. Johnson & Johnson Main Business
Table 101. Johnson & Johnson Latest Developments
Table 102. Gilead Sciences Basic Information, Targeted Therapy Drugs for Leukemia Manufacturing Base, Sales Area and Its Competitors
Table 103. Gilead Sciences Targeted Therapy Drugs for Leukemia Product Portfolios and Specifications
Table 104. Gilead Sciences Targeted Therapy Drugs for Leukemia Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 105. Gilead Sciences Main Business
Table 106. Gilead Sciences Latest Developments
Table 107. Abbvie Basic Information, Targeted Therapy Drugs for Leukemia Manufacturing Base, Sales Area and Its Competitors
Table 108. Abbvie Targeted Therapy Drugs for Leukemia Product Portfolios and Specifications
Table 109. Abbvie Targeted Therapy Drugs for Leukemia Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 110. Abbvie Main Business
Table 111. Abbvie Latest Developments
Table 112. Genentech Basic Information, Targeted Therapy Drugs for Leukemia Manufacturing Base, Sales Area and Its Competitors
Table 113. Genentech Targeted Therapy Drugs for Leukemia Product Portfolios and Specifications
Table 114. Genentech Targeted Therapy Drugs for Leukemia Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 115. Genentech Main Business
Table 116. Genentech Latest Developments
Table 117. Sanofi Basic Information, Targeted Therapy Drugs for Leukemia Manufacturing Base, Sales Area and Its Competitors
Table 118. Sanofi Targeted Therapy Drugs for Leukemia Product Portfolios and Specifications
Table 119. Sanofi Targeted Therapy Drugs for Leukemia Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 120. Sanofi Main Business
Table 121. Sanofi Latest Developments
Table 122. Amgen Basic Information, Targeted Therapy Drugs for Leukemia Manufacturing Base, Sales Area and Its Competitors
Table 123. Amgen Targeted Therapy Drugs for Leukemia Product Portfolios and Specifications
Table 124. Amgen Targeted Therapy Drugs for Leukemia Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 125. Amgen Main Business
Table 126. Amgen Latest Developments
Table 127. Roche Basic Information, Targeted Therapy Drugs for Leukemia Manufacturing Base, Sales Area and Its Competitors
Table 128. Roche Targeted Therapy Drugs for Leukemia Product Portfolios and Specifications
Table 129. Roche Targeted Therapy Drugs for Leukemia Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 130. Roche Main Business
Table 131. Roche Latest Developments
Table 132. GlaxoSmithKline Basic Information, Targeted Therapy Drugs for Leukemia Manufacturing Base, Sales Area and Its Competitors
Table 133. GlaxoSmithKline Targeted Therapy Drugs for Leukemia Product Portfolios and Specifications
Table 134. GlaxoSmithKline Targeted Therapy Drugs for Leukemia Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 135. GlaxoSmithKline Main Business
Table 136. GlaxoSmithKline Latest Developments
Table 137. AstraZeneca Basic Information, Targeted Therapy Drugs for Leukemia Manufacturing Base, Sales Area and Its Competitors
Table 138. AstraZeneca Targeted Therapy Drugs for Leukemia Product Portfolios and Specifications
Table 139. AstraZeneca Targeted Therapy Drugs for Leukemia Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 140. AstraZeneca Main Business
Table 141. AstraZeneca Latest Developments
Table 142. BeiGene Basic Information, Targeted Therapy Drugs for Leukemia Manufacturing Base, Sales Area and Its Competitors
Table 143. BeiGene Targeted Therapy Drugs for Leukemia Product Portfolios and Specifications
Table 144. BeiGene Targeted Therapy Drugs for Leukemia Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 145. BeiGene Main Business
Table 146. BeiGene Latest Developments
Table 147. Eli Lilly Basic Information, Targeted Therapy Drugs for Leukemia Manufacturing Base, Sales Area and Its Competitors
Table 148. Eli Lilly Targeted Therapy Drugs for Leukemia Product Portfolios and Specifications
Table 149. Eli Lilly Targeted Therapy Drugs for Leukemia Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 150. Eli Lilly Main Business
Table 151. Eli Lilly Latest Developments
Table 152. Merck Basic Information, Targeted Therapy Drugs for Leukemia Manufacturing Base, Sales Area and Its Competitors
Table 153. Merck Targeted Therapy Drugs for Leukemia Product Portfolios and Specifications
Table 154. Merck Targeted Therapy Drugs for Leukemia Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 155. Merck Main Business
Table 156. Merck Latest Developments
LIST OF FIGURES
Figure 1. Picture of Targeted Therapy Drugs for Leukemia
Figure 2. Targeted Therapy Drugs for Leukemia Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Targeted Therapy Drugs for Leukemia Sales Growth Rate 2019-2030 (Units)
Figure 7. Global Targeted Therapy Drugs for Leukemia Revenue Growth Rate 2019-2030 ($ millions)
Figure 8. Targeted Therapy Drugs for Leukemia Sales by Geographic Region (2019, 2023 & 2030) & ($ millions)
Figure 9. Targeted Therapy Drugs for Leukemia Sales Market Share by Country/Region (2023)
Figure 10. Targeted Therapy Drugs for Leukemia Sales Market Share by Country/Region (2019, 2023 & 2030)
Figure 11. Product Picture of Monoclonal Antibodies
Figure 12. Product Picture of Small-Molecule Drugs
Figure 13. Global Targeted Therapy Drugs for Leukemia Sales Market Share by Type in 2023
Figure 14. Global Targeted Therapy Drugs for Leukemia Revenue Market Share by Type (2019-2024)
Figure 15. Targeted Therapy Drugs for Leukemia Consumed in Acute Myeloid Leukemia (AML)
Figure 16. Global Targeted Therapy Drugs for Leukemia Market: Acute Myeloid Leukemia (AML) (2019-2024) & (Units)
Figure 17. Targeted Therapy Drugs for Leukemia Consumed in Chronic Myeloid Leukemia (CML)
Figure 18. Global Targeted Therapy Drugs for Leukemia Market: Chronic Myeloid Leukemia (CML) (2019-2024) & (Units)
Figure 19. Targeted Therapy Drugs for Leukemia Consumed in Acute Lymphoblastic Leukemia (ALL)
Figure 20. Global Targeted Therapy Drugs for Leukemia Market: Acute Lymphoblastic Leukemia (ALL) (2019-2024) & (Units)
Figure 21. Targeted Therapy Drugs for Leukemia Consumed in Chronic Lymphocytic Leukemia (CLL)
Figure 22. Global Targeted Therapy Drugs for Leukemia Market: Chronic Lymphocytic Leukemia (CLL) (2019-2024) & (Units)
Figure 23. Global Targeted Therapy Drugs for Leukemia Sale Market Share by Application (2023)
Figure 24. Global Targeted Therapy Drugs for Leukemia Revenue Market Share by Application in 2023
Figure 25. Targeted Therapy Drugs for Leukemia Sales by Company in 2023 (Units)
Figure 26. Global Targeted Therapy Drugs for Leukemia Sales Market Share by Company in 2023
Figure 27. Targeted Therapy Drugs for Leukemia Revenue by Company in 2023 ($ millions)
Figure 28. Global Targeted Therapy Drugs for Leukemia Revenue Market Share by Company in 2023
Figure 29. Global Targeted Therapy Drugs for Leukemia Sales Market Share by Geographic Region (2019-2024)
Figure 30. Global Targeted Therapy Drugs for Leukemia Revenue Market Share by Geographic Region in 2023
Figure 31. Americas Targeted Therapy Drugs for Leukemia Sales 2019-2024 (Units)
Figure 32. Americas Targeted Therapy Drugs for Leukemia Revenue 2019-2024 ($ millions)
Figure 33. APAC Targeted Therapy Drugs for Leukemia Sales 2019-2024 (Units)
Figure 34. APAC Targeted Therapy Drugs for Leukemia Revenue 2019-2024 ($ millions)
Figure 35. Europe Targeted Therapy Drugs for Leukemia Sales 2019-2024 (Units)
Figure 36. Europe Targeted Therapy Drugs for Leukemia Revenue 2019-2024 ($ millions)
Figure 37. Middle East & Africa Targeted Therapy Drugs for Leukemia Sales 2019-2024 (Units)
Figure 38. Middle East & Africa Targeted Therapy Drugs for Leukemia Revenue 2019-2024 ($ millions)
Figure 39. Americas Targeted Therapy Drugs for Leukemia Sales Market Share by Country in 2023
Figure 40. Americas Targeted Therapy Drugs for Leukemia Revenue Market Share by Country (2019-2024)
Figure 41. Americas Targeted Therapy Drugs for Leukemia Sales Market Share by Type (2019-2024)
Figure 42. Americas Targeted Therapy Drugs for Leukemia Sales Market Share by Application (2019-2024)
Figure 43. United States Targeted Therapy Drugs for Leukemia Revenue Growth 2019-2024 ($ millions)
Figure 44. Canada Targeted Therapy Drugs for Leukemia Revenue Growth 2019-2024 ($ millions)
Figure 45. Mexico Targeted Therapy Drugs for Leukemia Revenue Growth 2019-2024 ($ millions)
Figure 46. Brazil Targeted Therapy Drugs for Leukemia Revenue Growth 2019-2024 ($ millions)
Figure 47. APAC Targeted Therapy Drugs for Leukemia Sales Market Share by Region in 2023
Figure 48. APAC Targeted Therapy Drugs for Leukemia Revenue Market Share by Region (2019-2024)
Figure 49. APAC Targeted Therapy Drugs for Leukemia Sales Market Share by Type (2019-2024)
Figure 50. APAC Targeted Therapy Drugs for Leukemia Sales Market Share by Application (2019-2024)
Figure 51. China Targeted Therapy Drugs for Leukemia Revenue Growth 2019-2024 ($ millions)
Figure 52. Japan Targeted Therapy Drugs for Leukemia Revenue Growth 2019-2024 ($ millions)
Figure 53. South Korea Targeted Therapy Drugs for Leukemia Revenue Growth 2019-2024 ($ millions)
Figure 54. Southeast Asia Targeted Therapy Drugs for Leukemia Revenue Growth 2019-2024 ($ millions)
Figure 55. India Targeted Therapy Drugs for Leukemia Revenue Growth 2019-2024 ($ millions)
Figure 56. Australia Targeted Therapy Drugs for Leukemia Revenue Growth 2019-2024 ($ millions)
Figure 57. China Taiwan Targeted Therapy Drugs for Leukemia Revenue Growth 2019-2024 ($ millions)
Figure 58. Europe Targeted Therapy Drugs for Leukemia Sales Market Share by Country in 2023
Figure 59. Europe Targeted Therapy Drugs for Leukemia Revenue Market Share by Country (2019-2024)
Figure 60. Europe Targeted Therapy Drugs for Leukemia Sales Market Share by Type (2019-2024)
Figure 61. Europe Targeted Therapy Drugs for Leukemia Sales Market Share by Application (2019-2024)
Figure 62. Germany Targeted Therapy Drugs for Leukemia Revenue Growth 2019-2024 ($ millions)
Figure 63. France Targeted Therapy Drugs for Leukemia Revenue Growth 2019-2024 ($ millions)
Figure 64. UK Targeted Therapy Drugs for Leukemia Revenue Growth 2019-2024 ($ millions)
Figure 65. Italy Targeted Therapy Drugs for Leukemia Revenue Growth 2019-2024 ($ millions)
Figure 66. Russia Targeted Therapy Drugs for Leukemia Revenue Growth 2019-2024 ($ millions)
Figure 67. Middle East & Africa Targeted Therapy Drugs for Leukemia Sales Market Share by Country (2019-2024)
Figure 68. Middle East & Africa Targeted Therapy Drugs for Leukemia Sales Market Share by Type (2019-2024)
Figure 69. Middle East & Africa Targeted Therapy Drugs for Leukemia Sales Market Share by Application (2019-2024)
Figure 70. Egypt Targeted Therapy Drugs for Leukemia Revenue Growth 2019-2024 ($ millions)
Figure 71. South Africa Targeted Therapy Drugs for Leukemia Revenue Growth 2019-2024 ($ millions)
Figure 72. Israel Targeted Therapy Drugs for Leukemia Revenue Growth 2019-2024 ($ millions)
Figure 73. Turkey Targeted Therapy Drugs for Leukemia Revenue Growth 2019-2024 ($ millions)
Figure 74. GCC Countries Targeted Therapy Drugs for Leukemia Revenue Growth 2019-2024 ($ millions)
Figure 75. Manufacturing Cost Structure Analysis of Targeted Therapy Drugs for Leukemia in 2023
Figure 76. Manufacturing Process Analysis of Targeted Therapy Drugs for Leukemia
Figure 77. Industry Chain Structure of Targeted Therapy Drugs for Leukemia
Figure 78. Channels of Distribution
Figure 79. Global Targeted Therapy Drugs for Leukemia Sales Market Forecast by Region (2025-2030)
Figure 80. Global Targeted Therapy Drugs for Leukemia Revenue Market Share Forecast by Region (2025-2030)
Figure 81. Global Targeted Therapy Drugs for Leukemia Sales Market Share Forecast by Type (2025-2030)
Figure 82. Global Targeted Therapy Drugs for Leukemia Revenue Market Share Forecast by Type (2025-2030)
Figure 83. Global Targeted Therapy Drugs for Leukemia Sales Market Share Forecast by Application (2025-2030)
Figure 84. Global Targeted Therapy Drugs for Leukemia Revenue Market Share Forecast by Application (2025-2030)
Figure 1. Picture of Targeted Therapy Drugs for Leukemia
Figure 2. Targeted Therapy Drugs for Leukemia Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Targeted Therapy Drugs for Leukemia Sales Growth Rate 2019-2030 (Units)
Figure 7. Global Targeted Therapy Drugs for Leukemia Revenue Growth Rate 2019-2030 ($ millions)
Figure 8. Targeted Therapy Drugs for Leukemia Sales by Geographic Region (2019, 2023 & 2030) & ($ millions)
Figure 9. Targeted Therapy Drugs for Leukemia Sales Market Share by Country/Region (2023)
Figure 10. Targeted Therapy Drugs for Leukemia Sales Market Share by Country/Region (2019, 2023 & 2030)
Figure 11. Product Picture of Monoclonal Antibodies
Figure 12. Product Picture of Small-Molecule Drugs
Figure 13. Global Targeted Therapy Drugs for Leukemia Sales Market Share by Type in 2023
Figure 14. Global Targeted Therapy Drugs for Leukemia Revenue Market Share by Type (2019-2024)
Figure 15. Targeted Therapy Drugs for Leukemia Consumed in Acute Myeloid Leukemia (AML)
Figure 16. Global Targeted Therapy Drugs for Leukemia Market: Acute Myeloid Leukemia (AML) (2019-2024) & (Units)
Figure 17. Targeted Therapy Drugs for Leukemia Consumed in Chronic Myeloid Leukemia (CML)
Figure 18. Global Targeted Therapy Drugs for Leukemia Market: Chronic Myeloid Leukemia (CML) (2019-2024) & (Units)
Figure 19. Targeted Therapy Drugs for Leukemia Consumed in Acute Lymphoblastic Leukemia (ALL)
Figure 20. Global Targeted Therapy Drugs for Leukemia Market: Acute Lymphoblastic Leukemia (ALL) (2019-2024) & (Units)
Figure 21. Targeted Therapy Drugs for Leukemia Consumed in Chronic Lymphocytic Leukemia (CLL)
Figure 22. Global Targeted Therapy Drugs for Leukemia Market: Chronic Lymphocytic Leukemia (CLL) (2019-2024) & (Units)
Figure 23. Global Targeted Therapy Drugs for Leukemia Sale Market Share by Application (2023)
Figure 24. Global Targeted Therapy Drugs for Leukemia Revenue Market Share by Application in 2023
Figure 25. Targeted Therapy Drugs for Leukemia Sales by Company in 2023 (Units)
Figure 26. Global Targeted Therapy Drugs for Leukemia Sales Market Share by Company in 2023
Figure 27. Targeted Therapy Drugs for Leukemia Revenue by Company in 2023 ($ millions)
Figure 28. Global Targeted Therapy Drugs for Leukemia Revenue Market Share by Company in 2023
Figure 29. Global Targeted Therapy Drugs for Leukemia Sales Market Share by Geographic Region (2019-2024)
Figure 30. Global Targeted Therapy Drugs for Leukemia Revenue Market Share by Geographic Region in 2023
Figure 31. Americas Targeted Therapy Drugs for Leukemia Sales 2019-2024 (Units)
Figure 32. Americas Targeted Therapy Drugs for Leukemia Revenue 2019-2024 ($ millions)
Figure 33. APAC Targeted Therapy Drugs for Leukemia Sales 2019-2024 (Units)
Figure 34. APAC Targeted Therapy Drugs for Leukemia Revenue 2019-2024 ($ millions)
Figure 35. Europe Targeted Therapy Drugs for Leukemia Sales 2019-2024 (Units)
Figure 36. Europe Targeted Therapy Drugs for Leukemia Revenue 2019-2024 ($ millions)
Figure 37. Middle East & Africa Targeted Therapy Drugs for Leukemia Sales 2019-2024 (Units)
Figure 38. Middle East & Africa Targeted Therapy Drugs for Leukemia Revenue 2019-2024 ($ millions)
Figure 39. Americas Targeted Therapy Drugs for Leukemia Sales Market Share by Country in 2023
Figure 40. Americas Targeted Therapy Drugs for Leukemia Revenue Market Share by Country (2019-2024)
Figure 41. Americas Targeted Therapy Drugs for Leukemia Sales Market Share by Type (2019-2024)
Figure 42. Americas Targeted Therapy Drugs for Leukemia Sales Market Share by Application (2019-2024)
Figure 43. United States Targeted Therapy Drugs for Leukemia Revenue Growth 2019-2024 ($ millions)
Figure 44. Canada Targeted Therapy Drugs for Leukemia Revenue Growth 2019-2024 ($ millions)
Figure 45. Mexico Targeted Therapy Drugs for Leukemia Revenue Growth 2019-2024 ($ millions)
Figure 46. Brazil Targeted Therapy Drugs for Leukemia Revenue Growth 2019-2024 ($ millions)
Figure 47. APAC Targeted Therapy Drugs for Leukemia Sales Market Share by Region in 2023
Figure 48. APAC Targeted Therapy Drugs for Leukemia Revenue Market Share by Region (2019-2024)
Figure 49. APAC Targeted Therapy Drugs for Leukemia Sales Market Share by Type (2019-2024)
Figure 50. APAC Targeted Therapy Drugs for Leukemia Sales Market Share by Application (2019-2024)
Figure 51. China Targeted Therapy Drugs for Leukemia Revenue Growth 2019-2024 ($ millions)
Figure 52. Japan Targeted Therapy Drugs for Leukemia Revenue Growth 2019-2024 ($ millions)
Figure 53. South Korea Targeted Therapy Drugs for Leukemia Revenue Growth 2019-2024 ($ millions)
Figure 54. Southeast Asia Targeted Therapy Drugs for Leukemia Revenue Growth 2019-2024 ($ millions)
Figure 55. India Targeted Therapy Drugs for Leukemia Revenue Growth 2019-2024 ($ millions)
Figure 56. Australia Targeted Therapy Drugs for Leukemia Revenue Growth 2019-2024 ($ millions)
Figure 57. China Taiwan Targeted Therapy Drugs for Leukemia Revenue Growth 2019-2024 ($ millions)
Figure 58. Europe Targeted Therapy Drugs for Leukemia Sales Market Share by Country in 2023
Figure 59. Europe Targeted Therapy Drugs for Leukemia Revenue Market Share by Country (2019-2024)
Figure 60. Europe Targeted Therapy Drugs for Leukemia Sales Market Share by Type (2019-2024)
Figure 61. Europe Targeted Therapy Drugs for Leukemia Sales Market Share by Application (2019-2024)
Figure 62. Germany Targeted Therapy Drugs for Leukemia Revenue Growth 2019-2024 ($ millions)
Figure 63. France Targeted Therapy Drugs for Leukemia Revenue Growth 2019-2024 ($ millions)
Figure 64. UK Targeted Therapy Drugs for Leukemia Revenue Growth 2019-2024 ($ millions)
Figure 65. Italy Targeted Therapy Drugs for Leukemia Revenue Growth 2019-2024 ($ millions)
Figure 66. Russia Targeted Therapy Drugs for Leukemia Revenue Growth 2019-2024 ($ millions)
Figure 67. Middle East & Africa Targeted Therapy Drugs for Leukemia Sales Market Share by Country (2019-2024)
Figure 68. Middle East & Africa Targeted Therapy Drugs for Leukemia Sales Market Share by Type (2019-2024)
Figure 69. Middle East & Africa Targeted Therapy Drugs for Leukemia Sales Market Share by Application (2019-2024)
Figure 70. Egypt Targeted Therapy Drugs for Leukemia Revenue Growth 2019-2024 ($ millions)
Figure 71. South Africa Targeted Therapy Drugs for Leukemia Revenue Growth 2019-2024 ($ millions)
Figure 72. Israel Targeted Therapy Drugs for Leukemia Revenue Growth 2019-2024 ($ millions)
Figure 73. Turkey Targeted Therapy Drugs for Leukemia Revenue Growth 2019-2024 ($ millions)
Figure 74. GCC Countries Targeted Therapy Drugs for Leukemia Revenue Growth 2019-2024 ($ millions)
Figure 75. Manufacturing Cost Structure Analysis of Targeted Therapy Drugs for Leukemia in 2023
Figure 76. Manufacturing Process Analysis of Targeted Therapy Drugs for Leukemia
Figure 77. Industry Chain Structure of Targeted Therapy Drugs for Leukemia
Figure 78. Channels of Distribution
Figure 79. Global Targeted Therapy Drugs for Leukemia Sales Market Forecast by Region (2025-2030)
Figure 80. Global Targeted Therapy Drugs for Leukemia Revenue Market Share Forecast by Region (2025-2030)
Figure 81. Global Targeted Therapy Drugs for Leukemia Sales Market Share Forecast by Type (2025-2030)
Figure 82. Global Targeted Therapy Drugs for Leukemia Revenue Market Share Forecast by Type (2025-2030)
Figure 83. Global Targeted Therapy Drugs for Leukemia Sales Market Share Forecast by Application (2025-2030)
Figure 84. Global Targeted Therapy Drugs for Leukemia Revenue Market Share Forecast by Application (2025-2030)
